Introduction
Dysphagia, pain and food impaction experienced by patients with eosinophilic esophagitis (EoE) result from a complex inflammatory cascade. If uncontrolled, this inflammation may lead to esophageal structural remodeling, further exacerbating the burden of EoE. Corticosteroids have demonstrated the ability to alleviate inflammation in EoE, although their use may be limited by challenges in delivery to the esophagus, class-related side effects and poor medical adherence. EP-104GI offers a potential novel treatment option as a local, long-acting corticosteroid formulation of fluticasone propionate to be injected in the esophageal wall during routine endoscopy. We report here on improvements in inflammatory and structural histopathological features of EoE during dose escalation of EP-104GI in the RESOLVE trial.
Aims & Methods
RESOLVE (NCT05608681) is a two-part, phase 1b/2, multicenter trial to assess the feasibility, safety, tolerability, efficacy and pharmacokinetics of EP-104GI treatment in adult participants with EoE. In a first, phase 1b open-label dose escalation part, EP-104GI is injected once at baseline during endoscopy in the esophageal wall in cohorts with escalating number of injection sites or dose per site (n=3/cohort). Participants were followed for up to 24 (4x1mg, 8x1mg, 8x2.5mg and 12x2.5mg) or 52 weeks (12x4mg, 16x4mg, 20x4mg, 20x6mg and 20x8mg). Esophageal biopsies were collected during endoscopy 12- and 36-weeks following EP-104GI administration. Histopathological disease activity was assessed using the Eosinophilic Esophagitis Histology Scoring System (EoEHSS), measuring the severity (grade) and extent (stage) of inflammatory and structural features of EoE.
Results
All dose cohorts assessed 36 weeks following EP-104GI administration showed histopathological improvements relative to baseline as evaluated by EoEHSS. Overall, administration of EP-104GI was generally safe and well tolerated. Improvements in EoE histopathology resulted from decreases in both inflammatory and structural features. Dose cohorts 12x4mg, 16x4mg, 20x4mg, 20x6mg and 20x8mg showed relative decreases from baseline in inflammatory sub scores (grade/stage) of -64%/-66%, -48%/-50%, -45%/-49%, -37%/-11%, and -93/-94%, respectively. Respective relative changes from baseline in architectural (structural) sub scores of -42%/-45%, -34%/-20%, -21/-31%, -10%/-13%, and -83%/-87%. The highest dose cohort assayed (20x8mg) demonstrated (grade/stage) improvements in individual inflammatory features of eosinophil infiltration, eosinophil abscesses, eosinophil surface layering and surface epithelial alteration of -89/-92%, -100%/-100%, -100%/-100%, and -93%/-91%, respectively. Concurrently, individual structural features of basal cell hyperplasia, distended intercellular space and lamina propria fibrosis showed (grade/stage) improvements of -87%/-89%, -72%/-81%, and -83/-83%, respectively.
Conclusion
Single administration of EP-104GI can result in broad improvements across both inflammatory and structural histopathology features of participants with EoE for 36 weeks. Improvements over a longer period and in a greater number of participants will be assessed in the dose-optimization, phase 2 part of the RESOLVE trial.